EVT 302: MAO-B inhibitor

EVT 302 MAO-B inhibitor: Orally active, potent, highly selective and reversible inhibitor of MAO-B

• In development for smoking cessation; potential for disease modification in Alzheimer's disease.
• High degree of selectivity will allow dosing of EVT 302 to achieve complete inhibition of MAO-B without the liability associated with MAO-A inhibition.

First Phase II study in smoking cessation underway

MAO-B inhibition in smoker's brain

Evotec has successfully completed a Phase I safety and tolerability trial with 4 weeks dosing of EVT 302. In addition, single and repeat dose PET studies have been conducted to study brain MAO-B inhibition with EVT 302 to assist dose selection for Phase II.

An additional Phase I study is currently in progress to confirm that EVT 302 lacks the interaction with tyramine-rich foods ('cheese effect') that is seen with less selective compounds. Results from this study are expected in 1H 2008. The Phase I program has been designed to support development of EVT 302 as a disease modifying therapy in Alzheimer's.

Evotec commenced the first Phase II study of EVT 302 in Feb 2008 which is designed to investigate the influence of EVT 302 on craving and withdrawal symptoms after short-term deprivation of cigarettes. A second Phase II study in smoking cessation will commence later this year.

For the latest press release announcing the start of Phase II clinical trials for EVT 302 (28 Feb 2008) click here